BDSX News and Press, Biodesix Inc. From 10/11/22

Third quarter 2022 core lung diagnostic testing revenues growth up 96% to 103% compared to third quarter 2021 Biodesix, Inc. (NASDAQ: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the Company expects to report th...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: oneinchpunch/Shutterstock.com We’re taking a look at the biggest pre-market stock movers traders need to know about on Thursday morning! Moving stocks this morning are clinical trial results, public s...

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will participate in two upcoming investor conferences: Morgan Stanley 20th Annual Global Healthcar...

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced it has been recognized in the Healthcare Technology Report’s Top 100 Healthcare Technology Companies of 2022. The company develops and commercia...

Biodesix, Inc. (BDSX) Q2 2022 Earnings Conference Call August 4, 2022 08:00 ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Conference Call Participants Bri...

Image source: The Motley Fool. Biodesix, Inc. (NASDAQ: BDSX) Q2 2022 Earnings Call Aug 04, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Biodesix, Inc. (BDSX) Q2 2022 Earnings Call Transcript

Biodesix press release ( NASDAQ: BDSX ): Q2 GAAP EPS of -$0.40 beats by $0.07 . Revenue of $10.95M (-8.0% Y/Y) beats by $2.12M . The company reaffirms its 2022 financial outlook and expects to generate between $37.5M and $39.5M in total revenue in 2022 vs. cons...

Second quarter 2022 core Lung Diagnostic revenue of $7.3 million increased 52% over the comparable period in 2021; Received Medicare coverage for the Nodify CDT® Lung Nodule Test; Announced strategic arrangements during the quarter (Royal Philips, Memorial Sloan K...

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the Canaccord Genuity 42nd Annual Growth Conference being held August 8-11, 2022. ...

Gainers: Sunshine Biopharma ( SBFM ) +26% . InflaRx IFRX +14% . Talaris Therapeutics ( TALS ) +8% . Nutriband ( NTRB ) +7% . Biodesix ( BDSX ) +5% . Losers: Revelation Biosciences REVB -52% . Virax Biolabs VR...